Development and validation of a polygenic hazard score to predict prognosis and adjuvant chemotherapy benefit in early-stage non-small cell lung cancer.

We further validated the PHS in an independent population (PLCO ACT set, n=56) and a similar trend was observed (HR =0.33, 95% CI: 0.04–2.48, P = 0.260; Figure 2E ), although the results did not reach statistical significance likely due to the limited sample size.

also in 111,027 other papers